We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Drug Resistance Testing Is Essential for TB Prognosis

By LabMedica International staff writers
Posted on 08 Sep 2010
Tuberculosis is diagnosed in the laboratory by staining sputum smears with the Ziehl-Neelsen acid-fast stain.

However, multi-drug-resistant tubercle bacilli (MDR-TB) cannot be identified by this method. More...
The standard way to test for drug susceptibility is by culturing the bacteria Mycobacterium tuberculosis on Löwenstein-Jensen (LJ) or by the microscopic observation drug susceptibility (MODS) assay.

A study on MDR-TB with 93 participants in a larger study of directly observed therapy was conducted at the Imperial College London (London, UK). The median time for smears and cultures to turn negative was 17.5 days and 38.5 days, respectively. Most patients (90%) were smear-negative by 47.5 days and culture-negative by 93 days. In Peru, for example, the authors found that only 25% of patients with culture-positive MDR-TB were sputum smear-positive after two months of anti-tuberculosis treatment.

The authors point out that when treatment began, 66.7% of patients with culture-positive MDR-TB had positive sputum smears. After two months of treatment, only 25% had positive smears, and after four months, only 20% were smear-positive.

However, more than half of MDR patients remained culture positive even after six months of treatment. Overall, among patients who remained culture positive after two months of directly observed treatment, only 18.8% were sputum smear positive. Persistent smear positivity at day 60 is a poor predictor of MDR and thus not a good surrogate for drug susceptibility testing.

David A. Moore, M.D., the senior author of the study, said, "The industrialized-world convention of universal baseline drug sensitivity testing for tuberculosis patients should become the standard of care in multidrug resistance-affected resource-limited settings. Patients are more infectious on treatment than we previously believed, even when they are on the right treatment." This is important in developing countries where diagnosis of drug resistance is delayed due to lack of drug sensitivity testing and patients remain infectious for longer periods.

The study, published in August 2010 in Clinical Infectious Diseases demonstrates that patients with TB who have fully susceptible disease remain sputum culture positive for much longer than is conventionally believed, regardless of baseline smear status. The influence of baseline sputum bacillary load on smear and culture conversion is relatively minor except at very high smear positivity. Conversion from smear or culture positivity to negativity is significantly delayed by both MDR and resistance that is not MDR, but the relative importance varies, depending on the drug susceptibility test method used to define resistance.

Related Links:
Imperial College London


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.